Health Economics and Outcome Research (HEOR) helps decision makers and payers in allocating the scarce resources in healthcare sector. iDNA has a HEOR division specializing in the field of lung cancer screening, cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD). We can provide HEOR services in the following aspects: economic evaluation, literature review, real-world evidence solutions, network meta-analysis and more. Our HEOR activities are strengthened by the collaborations with our academic partners at the University of Groningen and the Erasmus MC.

At iDNA, health economists and industry experts are ready to work with you to develop the most suitable model to answer your research questions in the field of lung cancer screening, CVD and COPD. For example, the cost-effectiveness analysis, the budget impact analysis, the cost-benefit analysis. In addition, iDNA also work with strategic partners to ensure that we have the top experts from relevant fields to provide the insights it deserves.

iDNA pairs the clinical experience with methodological expertise in literature reviews, for lung cancer screening, CVD and COPD. Whether it be informing an economic evaluation, developing the value message, or producing a stand-alone publication, the HEOR team is experienced in completing scoping reviews, rapid reviews, and robust systematic reviews, utilizing established Cochrane Collaboration methodology.

iDNA has extensive experience in facilitating the implementation of lung cancer screening. We therefore have the potential to provide real world solutions, like evidence generation for early-stage lung cancer patients and micro-costing studies, through de-identified real-world data. Real world projects can be designed to provide researchers and decision makers with the evidence to bridge data gaps, thus the opportunities to better allocate the scarce healthcare resources.